EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.


EQRx was founded in 2020 by a group of passionate innovators and scientists with backgrounds in Chemistry, Biochemistry, and Medicine. We are headquartered in San Francisco, with offices in Berlin and London.

We’re facing one of the biggest healthcare challenges of our time: Every day, people are diagnosed with life-changing conditions, but can’t afford the medicines they need. And that’s just accepted as the status quo. lWE BELIEVE THERE’S A BETTER WAY. So, we decided it was time for a change. At EQRx, we’re trailblazing a revolution. To make medicines more affordable for people who need them To bring back trust between the pharma industry and patients To make drug pricing transparent

EQRx will build a better healthcare system where the names of people and communities come first, and everyone has access to the medicines they need at a price they can afford.

Key Team

Dr. Eric E. Hedrick M.D. (Chief Physician Exec.)

Mr. Robert Forrester LL.B. (Co-Founder & Advisor)

Dr. Peter B. Bach M.D., MAPP (Co-Founder & Advisor)

Sir Andrew Dillon CBE (Co-Founder & Advisor)

Mr. Daniel Hoey (Chief of Technical Operations)

Ms. Dina Ciarimboli J.D. (Gen. Counsel & Corp. Sec.)

Ms. Rona Anhalt (Chief People Officer)

Recognition and Awards
EQRx won 13 awards in 2022 and 14 awards in 2021. In 2022, EQRx won for Best Company for Women 2022, Best CEO 2022, Best Company Culture 2022, Best Company Perks & Benefits, Best Company Work-Life Balance, Best Company Compensation, Happiest Employees, Best Career Growth 2022, Best Leadership Teams 2022, Best CEOs for Diversity 2022, Best CEOs for Women 2022, Best Places to Work in Boston 2022 and Best Company Outlook 2022. In 2021, EQRx won for Best Company for Diversity 2021, Best Company for Women 2021, Best CEO 2021, Best Company Culture 2021, Best Company Perks & Benefits, Best Company Work-Life Balance, Best Company Compensation, Best Company Happiness, Best Career Growth 2021, Best Leadership Teams 2021, Best CEOs for Diversity 2021, Best CEOs for Women 2021, Best Places to Work in Boston 2021 and Best Company Outlook 2021. Based on 3,563 ratings and 125 participants, employees at EQRx are very satisfied with their work experience. The overall culture score, 92/100 or A+, incorporates employee ratings based on their feedback on the Work Culture, Outlook, CEO Rating and more.

Leadership team

Mr. Alexis A. Borisy A.M. (Founder & Exec. Chairman of Board of Directors)

Ms. Melanie I. Nallicheri (CEO & Director)

Ms. Jamilu E. Rubin (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Cambridge, Massachusetts, United States
Company Registration
SEC CIK number: 0001843762
Traded as
Social Media
Fri Mar 01 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium